Literature DB >> 1828919

Differential regulation of adenovirus late transcriptional units by the products of early region.

E Bridge1, C Hemström, U Pettersson.   

Abstract

Normal accumulation of adenoviral late mRNAs derived from the major late promoter, is mediated independently by either the ORF 6 or the ORF 3 product of E4. We have examined the role of E4 products in the expression of three late messages that are derived from outside the major late transcriptional unit: polypeptide IX mRNA, IVa2 mRNA, and messages from the E2 late promoter. We conclude that the late RNA accumulation phenotypes of E4 mutants can be broken down into two components. The effect on nuclear RNA accumulation, which is mediated independently by either the ORF 6 or ORF 3 products, is targeted to late messages derived from the major late transcriptional unit. A second small effect, that is mediated only by ORF 6, is needed for optimal accumulation of mRNA in the cytoplasm, and affects major late promoter derived messages as well as the message for polypeptide IX. The levels of IVa2 and E2 late messages are not reduced in cells infected with E4 negative mutants.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1828919     DOI: 10.1016/0042-6822(91)90138-2

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  3 in total

1.  Control of adenovirus early gene expression during the late phase of infection.

Authors:  S P Fessler; C S Young
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

2.  Spliced exons of adenovirus late RNAs colocalize with snRNP in a specific nuclear domain.

Authors:  E Bridge; K U Riedel; B M Johansson; U Pettersson
Journal:  J Cell Biol       Date:  1996-10       Impact factor: 10.539

3.  Adipocyte commitment of 3T3-L1 cells is required to support human adenovirus 36 productive replication concurrent with altered lipid and glucose metabolism.

Authors:  Verónica Márquez; Grisel Ballesteros; Thomas Dobner; Ramón A González
Journal:  Front Cell Infect Microbiol       Date:  2022-09-27       Impact factor: 6.073

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.